ArticlePharmaceuticals (Basel, Switzerland)2024

Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug-Drug Interaction Study.

Irene Moreno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.